Ann: Security Class Reinstatement to Quotation- OPTOB, page-603

Yes , of course, it had lots of winking emojis , and I was trying to sound like a slick salesperson.

A more realistic $4–$5 in the near term is still a 10x bagger a crazy value for me. That being said, while I was being tongue-in-cheek about it, my point was that in Australia, we often think very colloquially. I’m as guilty as anyone of not looking at or pricing at things from a global perspective.

For big pharma, the $1.2B that OPT is worth today is really just small change—honestly, it would be a rounding error in the context of a competitive negotiation. Depending on P3 outcome of course if there are 5+ letters and in 2026 OPT gets the biologics license and the global deals then $10 is very realistic in 2 years.